Glenmark Pharmaceuticals targets $1.6bn revenue by 2030

Glenmark Pharmaceuticals announced plans to reach consolidated revenue of $1.6 billion by FY25, with over 60% from branded markets rising to over 70% by FY30.

The company targets medium-term revenue growth of 12-14% CAGR, R&D investment at 7-7.5% of revenue, and consolidated EBITDA margin reaching 23%. It also aims to maintain 20% consolidated ROCE and ROE.

Glenmark reported R&D expenses of ₹9,305 million in FY25 and growth CAPEX of ₹7,496 million.